Dear SBC Community,
2017 was both busy and successful for Stevenage Bioscience Catalyst. Our five-year review, 'Innovation with Impact' gave us the chance to celebrate all that had been achieved since 2012, while the East of England Science and Innovation Audit showed us the wealth of assets in the region. Leading the Life Sciences part of the Audit has given us some great ideas on how to work collaboratively for healthcare benefit in the future. We welcomed a range of new companies, including Autifony Therapeutics, Kandy Therapeutics, LiFT BioSciences , Freeline Therapeutics , Gyroscope Therapeutics and Crick spin out Achilles Therapeutics while others expanded rapidly. On the funding side, 2017 was a record breaking year for our companies who raised in excess of £100m taking the total to over £340m raised by tenants so far. News highlights from some of our other companies are shown below. Finally, we were very sad to see our inaugural CEO Martino Picardo leave, but look forward to welcoming Sally Ann Forsyth to SBC soon. As our new CEO, Sally Ann will be leading SBC through its next phase of development in 2018 and beyond.